文献速递肺栓塞与肺血管病

S100A12作为肺动脉高压心输出量恶化与死亡标志物

S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension.
PubMed 文献 · Respirology · 2018-04-02

本研究基于两个中心良好表型的肺动脉高压队列,评估血清S100A12浓度与死亡率的关系。发现队列中PH患者S100A12显著高于对照(29.8 vs 15.7 ng/mL,P<0.001),且与心输出量负相关(r=-0.58,P<0.001)。汇总两队列,PAH与非PAH PH患者S100A12均高于健康外部对照(32.6、30.9、15.7 ng/mL,P<0.001),且S100A12与全因死亡风险增加相关(发现队列P=0.008,验证队列P<0.001)。

要点

  • PH患者血清S100A12水平显著高于对照,且与心输出量呈负相关。
  • S100A12水平升高与PH患者全因死亡风险增加相关。
  • S100A12可能作为PH预后评估的潜在生物标志物。

核心结论

  • PH患者S100A12水平升高,且与死亡率增加相关。

研究设计与样本

  • 探索性微阵列分析基于特发性肺纤维化患者外周血单核细胞。
  • 研究在两个其他中心良好表型的PH队列中评估血清S100A12与死亡率的关联,发现队列n=51,验证队列n=40。

主要发现

  • 发现队列中PH患者S100A12显著高于对照(29.8 vs 15.7 ng/mL,P<0.001)。
  • PH患者S100A12与心输出量负相关(r=-0.58,P<0.001)。
  • 汇总两队列,PAH和非PAH PH患者S100A12均高于健康外部对照(32.6、30.9、15.7 ng/mL,P<0.001)。
  • S100A12与PH患者全因死亡风险增加相关,发现队列P=0.008,验证队列P<0.001。

临床怎么用

  • S100A12可能辅助PH患者风险分层和预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Molecular biomarkers are needed to refine prognostication and phenotyping of pulmonary hypertension (PH) patients. S100A12 is an emerging biomarker of various inflammatory diseases. This study aims to determine the prognostic value of S100A12 in PH. METHODS: Exploratory microarray analysis performed on peripheral blood mononuclear cells (PBMC) collected from idiopathic pulmonary fibrosis (IPF) patients suggested an association between S100A12 and both PH and mortality. So the current study was designed to evaluate for an association between S100A12 in peripheral blood collected from two well-phenotyped PH cohorts in two other centres to derive and validate an association between S100A12 protein serum concentrations and mortality. RESULTS: The majority of the patients in the discovery and validation cohorts were either World Health Organization (WHO) group 1 (pulmonary arterial hypertension (PAH)) or 3 (lung disease-associated) PH. In the discovery PH cohort, S100A12 was significantly increased in patients with PH (n = 51) compared to controls (n = 22) (29.8 vs 15.7 ng/mL, P < 0.001) and negatively correlated with cardiac output (r = -0.58, P < 0.001) in PH patients. When S100A12 data were pooled from both cohorts, PAH and non-PAH PH patients had higher S100A12 compared to healthy external controls (32.6, 30.9, 15.7 ng/mL; P < 0.001). S100A12 was associated with an increased risk in overall mortality in PH patients in both the discovery (n = 51; P = 0.008) and validation (n = 40; P < 0.001) cohorts. CONCLUSION: S100A12 levels are increased in PH patients and are associated with increased mortality.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Tzouvelekis A, Herazo-Maya JD, Ryu C, et al. S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. Respirology. 2018. PMID: 29611244. doi:10.1111/resp.13302

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。